ATLAS ACS-TIMI 46

ATLAS ACS-TIMI 46 compared the safety and efficacy of rivaroxaban, an oral direct factor Xa inhibitor, to placebo in patients with acute coronary syndromes. MAIN RESULTS: Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet. 2009 Jul 4;374(9683):29-38 PRESENTATIONS TIMI 46 Slides Atlas ACS2-TIMI 51 … Continue reading ATLAS ACS-TIMI 46